Correction to “Structure–Activity Relationship of Truncated 2,8-Disubstituted-Adenosine Derivatives as Dual A_2A/A₃ Adenosine Receptor Antagonists and Their Cancer Immunotherapeutic Activity”

Page 12253. In Scheme 4, the conditions (a) should be corrected, to read as follows: “(a) 17d, BSA, TMSOTf, CH₃CN, 80 °C, 5 h;”.

Page 12259. In the Experimental Section, the synthetic procedure of 20 should be corrected, to read as follows: “To a stirred suspension of 2-chloro-8-iodo-6-chloropurine (17d) (3.00 g, 7.38 mmol) in CH₃CN (150.0 mL) was dropwise added BSA (2.40 mL, 9.83 mmol) at room temperature under N₂ and the mixture was heated at 80 °C until obtaining clear brown solution. To the reaction mixture was quickly added 16 (2.00 g, 4.92 mmol) in CH₃CN (50.0 mL) and TMSOTf (0.89 mL, 4.92 mmol) and the mixture was stirred at 80 °C for 5 h. The reaction mixture was cooled to room temperature, quenched with saturated NaHCO₃ solution (100 mL), and diluted with EtOAc (100 mL). The layers were separated, and the aqueous layer was extracted with EtOAc (3 × 100 mL).The combined organic layers were washed successively with H₂O (50 mL), dried over anhydrous MgSO₄, filtered, and evaporated. The residue was purified by column chromatography (silica gel, hexanes/EtOAc, 10/1) to give 20 (1.50 g, 41%) as brown syrup…”.

Page 12260. In the Experimental Section, the synthetic procedure of 23 should be corrected, to read as follows: “To a stirred solution of 2,6-dichloro-8-iodopurine (19) (581 mg,1.84 mmol) in CH₃CN (10.0 mL) was dropwise added BSA (0.60 mL, 2.46 mmol) at room temperature under N₂…”.

Page 12264. In the Acknowledgments, the grant number in the first sentence should be corrected, to read as follows: “This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2022R1A6A1A-03046247)…”.